(3aR)-1,3a,8-Trimethyl-1 ,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl Phenylcarbamate and Methods of Treating or Preventing Neurodegeneration

A method of reducing the amount of a neurotoxic aggregating protein in a human subject, comprising administering to a human subject a pharmaceutical composition consisting of from about 1 mg to less than about 200 mg of posiphen or a pharmaceutically acceptable salt thereof together with one or more pharmaceutically acceptable excipients, on a once a day basis.

The method of claim 16, wherein said neurotoxic aggregating protein is selected from the group consisting of APP, Aβ, SOD, Tau, alpha-synuclein (SNCA), NAC, TSE prion, and HTT.

26-28. (canceled)

30-32. (canceled)

34-37. (canceled)

39-41. (canceled)

The method of claim 41, wherein said subject is suffering from a dementia selected from the group consisting of Alzheimer's disease, Down Syndrome, alpha-synucleopathies, Parkinson's disease, Huntington's disease, Prion's disease, Amyloid Lateral Sclerosis and a tauopathy.

43-61. (canceled)

The method of claim 1, wherein the half-life of posiphen in cerebrospinal fluid after administering is about 12 hours.

The method of claim 1, wherein the half-life of posiphen in plasma after administering is about 5 hours.

The method of claim 1, wherein the pharmaceutical composition includes from about 7.5 mg to less than about 200 mg of posiphen or a pharmaceutically acceptable salt thereof.

A method of ameliorating neurodegenerative processes in a human patient, comprising administering a pharmaceutical composition consisting of from about 7.5 mg to less than about 200 mg of posiphen or a pharmaceutically acceptable salt thereof together with one or more pharmaceutically acceptable excipients, on a once a day basis, such that the production of neurotoxic aggregating protein in the human patient is inhibited.

A method of inhibiting neural alpha-synuclein expression in a human patient, comprising administering a pharmaceutical composition consisting of from about 7.5 mg to less than about 160 mg of posiphen or a pharmaceutically acceptable salt thereof together with one or more pharmaceutically acceptable excipients, the inhibition of neural alpha-synuclein expression by the posiphen being potentiated by cellular iron.